

SCI PHARMTECH, INC. 旭富製藥科技

簡報

ISO 14001

BUREAU VERITAS
Certification



ISO 9001

BUREAU VERITAS
Certification



公司概況Profile



員工數Employee：202

設立日期：中華民國七十六年九月十八日

Date of establishment: Sep. 18, 1987

資本額Capital：新台幣697佰萬元(NTD 697mn)

營業項目Business：

原料藥API（33.85%）

中間體Intermediate（54.82%）

特用化學品 Custom-made chemicals（11.33%）

公司概況 Outline

	Y2013	Y2014 to date
歐洲 Europe	36.01%	43.37%
美洲 America	22.80%	23.07%
亞洲 Asia	24.00%	17.31%
國內 Taiwan	17.19%	15.25%
澳洲 Australia	0.00%	1.00%
合計 Total	100.00%	100.00%

製藥產業的上、中、下游 SCI's position

上游
Upstream

基本原料 RM



中間體 Intermediate:

生產原料藥之
中間步驟所產出之產品 Products before API



中游
Midstream

原料藥 API:

製劑中之有效成分 Treatable ingredient



下游

Downstream

製劑: 成品藥 Formulation

旭富營業範圍

SCI's businesses

營運概況-IS

Unit: K NTD

	2013	2014 to date
營收Sales	1,292,734	920,374
營業成本COGS	(895,753)	(620,173)
毛利Gross Profit	396,981	300,201
毛利率 GP Ratio	30.7%	32.6%
營業費用Operating Expenses	(191,122)	(116,618)
營業利益Operating Income	205,859	183,583
營業外損益Non-Operating In/Ex	(12,079)	35,543
稅前淨利 Net Profit before Tax	193,780	219,126
所得稅Income Tax	(33,842)	
本期淨利Net Profit after Tax	159,938	

產品組合-Products

Y2011	%	Y2012	%	Y2013	%
Di-VaNa	24.51%	V.A.	18.66%	PGA	18.31%
PGA	17.65%	PGA	16.61%	Di-VaNa	16.92%
V.A.	13.76%	Di-VaNa	15.97%	S20/38	8.39%
PPON	10.70%	PPON	7.88%	V.A.	8.23%
M85	5.25%	Pent-2	4.78%	LPF.Na	6.58%
Pent-2	3.73%	5-HMT	4.33%	PPON	6.53%
DBS	3.08%	M85	3.89%	5-HMT	4.51%
M115	2.55%	DBS	2.73%	PEB.Na	3.98%
M74	2.31%	M115	2.59%	NaVa	3.34%
NBE	1.87%	M74	2.18%	DBS	2.63%
Total	85.40%	Total	79.62%	Total	79.42%


No.	Product	%	Sales (NT\$)
1	PGA	16.42%	171,211,625
2	S20/38	11.80%	123,012,851
3	LPF.Na	8.02%	83,648,469
4	Di-VANa	7.16%	74,679,509
5	V.A.	6.78%	70,674,609
6	DBS	5.43%	56,637,640
7	PEB.Na	4.32%	45,009,722
8	NaVA	3.66%	38,161,228
9	5-HMT	3.54%	36,882,944
10	PPON	3.52%	36,718,089

產品介紹Products



產品介紹Product

● Pyrogallolaldehyde (PGA) - Benserazide



✓治療帕金森氏症之中間體

Intermediate for Parkinson's Disease

✓2個客戶

2 customers


✓2014 sales: 171 M

產品介紹Product

Anti-inflammatory (Loxoprofen sodium)

- ✓ 2012年銷售5佰萬 5 mn sales in 2012
- ✓ 2013年銷售85佰萬 85 mn sales in 2013
- ✓ 2014 sales:83.6 M
- ✓ 日本市場200-300公噸, 180美金/公斤
Japan market:200-300MT at USD 180/kg


S20/38



✓ 2014 sales:123M

產品介紹Product

● Divalproex Sodium (Di-Va)




- ✓ 學名藥於2009推出
- ✓ 12個客戶
- ✓ 2014 sales: 74.7 M

Generic came out in 2009
12 customers

產品介紹Product

Valproic Acid (VA)




✓ 20個客戶

20 customers

✓ 2014 sales: 70.7 M

產品介紹Product

Pentobarbital Sodium




- ✓ 鎮定安眠用之原料藥
- ✓ 4個客戶
- ✓ 2014 sales:45M

API used as calmative
4 customers


產品介紹Product

Sodium Valproate (NaVA)



- ✓ 22 客戶 22 customers
- ✓ 2014 sales: 38M

5-HMT – Ritonavir, Lopinavir



- ✓ 愛滋病藥物中間體
For AIDS treatment
- ✓ 2014 sales: 36.9M

產品介紹Product

Antidepressant (Duloxetine)

✓ 2013年底專利到期

Patent expired in the end of 2013

✓ 10個客戶

10 customers

Antidepressant (S-MMAA)

✓ Duloxetine之中間體

intermediate of Duloxetine

✓ 2014 sales: 12.5 M

產品介紹Product

- ✓ 5t: 15.3m sales
- ✓ Hydroxychloroquine sulfate: 12 m sales
- ✓ Propafenone: 10 m sales
- ✓ Cyclophosphamide: 1.4 m sales
- ✓ Lorcaserin



GMP Status(GMP現況)

<i>API</i>	<i>CGMP certified (TFDA)</i>	<i>CEP (EDQM)</i>	<i>DMF (USA)</i>	<i>MF (Japan)</i>	<i>DMF (Canada)</i>
Valproic Acid (*)	2003	2004	2003	2008	2008
Allopurinol	2004	2003	2011		
Probucol	2004		2004		
Sodium Valproate	2004	2006			
Divalproex Sodium (**)	2005		2005		2010
Bisoprolol Fumarate	2006				
Pentobarbital Sodium	2009	2011			
Propafenone Hydrochloride	2010	2012	2010	2012	2012
Methylphenidate HCl	2011	2014			
Duloxetine Hydrochloride	2012	2014	2010/2011		
Thiopental acid	2012				
Loxoprofen Sodium Hydrate	2012			2011	
Articaine Hydrochloride	2013	2014			
Hydroxychloroquine Sulfate	2014		2014		
Clindamycin Palmitate HCl			2011		
Cyclophosphamide			2012		

(*)(**) FDA inspection: Nov. 2005 / April 2012, (*) EDQM inspection: Nov. 2010

簡報完畢



敬請指教